Japan Lifeline Q2 FY2027: Record first-half sales, profit falls 17%

Japan Lifeline reported first-half revenue of ¥31.353 billion, up 7.1% from a year earlier, operating profit of ¥5.468 billion, down 17.4%, and net income attributable to owners of the parent of ¥4.430 billion, down 7.2%. Revenue was a record for the first half.

Gross profit increased just 2.6%, while selling, general and administrative expenses rose 14.8% to ¥12.55 billion. Key factors included:

• Research and development costs: Spending increased on new products such as the PFA system and on adapting Japan Lifeline's products for overseas markets.
• Personnel costs: Higher salary levels pushed expenses up.
• Acquisition-related costs: Outsourcing fees associated with acquisitions increased.
• Prior-year one-off factor: The company recorded a reversal of allowance for doubtful accounts in the year-earlier period, creating a drag on the year-on-year comparison.

The result was higher sales but lower profit as growth investment outpaced sales gains. Sales promotion for new products, revisions to official reimbursement prices and rising raw-material costs also contributed to a 2.5-percentage-point decline in the gross profit margin. Ordinary profit fell by a more modest 8.8%, supported by non-operating income including gains on investment securities and the reversal of the allowance for doubtful accounts.

Japan Lifeline does not report operating segments in its earnings release. The following figures show sales by product category. EP and ablation, along with newer business areas, led growth.

EP/ablation sales were ¥16.222 billion, up 10.3% from a year earlier. Atrial fibrillation ablation procedures increased by about 10%, lifting sales of intracardiac defibrillation catheters and hemostasis devices for femoral veins. The radiofrequency wire for atrial septal puncture, launched in March 2026, also gained traction faster than expected.

Cardiovascular sales rose 4.1% to ¥6.177 billion. The Frozen Elephant Trunk product maintained a high market share, while sales of abdominal stent grafts grew following stronger sales initiatives.

• Neurovascular: ¥1.696 billion, up 42.9%. New model launches and higher sales volumes contributed to growth.
• Gastroenterology: ¥1.057 billion, up 34.4%. Sales of a new biliary tube stent were strong, while supply shortages of competitors' products provided a tailwind. Excluding discontinued businesses, sales rose 41.6%.
• Rhythm devices: ¥6.198 billion, down 7.0%. Market adoption of competitors' leadless pacemakers and new S-ICD products weighed on sales.

Both established core products and newer areas expanded, while rhythm devices, which the company considers a stable business, faced a changing competitive landscape. Japan Lifeline plans to use its combination of manufacturer and trading-company capabilities to bring products suited to healthcare providers' needs to market quickly.

Japan Lifeline left its consolidated earnings forecast for FY2027 unchanged. First-half revenue was tracking slightly ahead of the company's initial assumptions, but it expects to spend in the second half on research and development costs that were delayed in the first half.

The approximate previous-year actual figures are reference values derived from the year-on-year changes in the company's forecast. The current forecast calls for revenue of ¥63.2 billion, up 6.8% from the previous year; operating profit of ¥10.7 billion, down 15.1%; and net income of ¥8 billion, down 14.4%. No forecast revisions were made.

The company said strong sales in EP and ablation, neurovascular and gastroenterology are offsetting weakness in rhythm devices. It expects sales to track its initial forecast in the second half, alongside higher spending on research and development. Whether sales growth can translate into profit growth remains a key focus.

Total assets stood at ¥80.005 billion at the end of the first half, down ¥205 million from the end of March 2026. The equity ratio rose to 82.9% from 82.1% at the previous fiscal year-end.

Cash and cash equivalents fell ¥782 million from the start of the period to ¥11.711 billion. Operating cash flow was below the year-earlier level because of increases in trade receivables and inventories, as well as corporate tax payments. Investing cash outflows narrowed, in part because of the recovery of long-term loans.

Japan Lifeline paid a ¥25 commemorative interim dividend and forecasts a regular year-end dividend of ¥56. The full-year dividend forecast is ¥81, up ¥27 from ¥54 in the previous year. The company disclosed no share buyback. Its high equity ratio gives it room to pursue growth investment alongside shareholder returns.

As a foothold for its U.S. business, Japan Lifeline established wholly owned subsidiary JLL Med USA Inc. and, on Oct. 1, 2026, made U.S.-based Cross Vascular Inc. a wholly owned indirect subsidiary. The acquisition was approved on Sept. 29, and the share purchase was completed after the end of the first-half reporting period.

The company's medium-term plan prioritizes the continued launch of competitive products, expansion into new fields, overseas sales growth, promotion of OEM manufacturing and management focused on capital efficiency. The acquisition is part of its effort to reduce reliance on the domestic market through globalization and build a pipeline of new products.

Japan Lifeline also plans to pursue research and development related to PFA, as well as opportunities in stent grafts and transcatheter aortic valve implantation (TAVI). Key indicators of longer-term growth will include how much the acquired business contributes to sales and profit, and whether the company can adapt products for overseas markets and strengthen its quality systems as planned.

An aging population and the shift toward minimally invasive treatment support market growth, but labor shortages at medical institutions, the official reimbursement system and product competition pose challenges to turning that growth into profit.

• Rising costs: A weaker yen and inflation could increase raw-material, logistics and personnel costs. Because official reimbursement prices limit the scope to pass on costs, margins could come under pressure.
• Product competition: Wider adoption of competing products such as leadless pacemakers and S-ICDs could further weaken rhythm-device sales.
• Research and development burden: Investment in areas such as PFA is increasing. If new product launches or market adoption are delayed, expenses could continue to run ahead of revenue.
• Overseas expansion and post-acquisition integration: Growing the U.S. business will require adapting products to local needs and establishing quality standards. If integration or commercialization of the acquired business falls behind plan, the expected growth benefits could be delayed.
• Pressure on healthcare capacity: Physician work-style reforms and staff shortages could affect procedure volumes and product adoption at medical facilities.

The company said it secured raw materials early and sees no particular impact on product supply from the situation in the Middle East at present. It will continue to monitor changes in procurement costs and supply conditions.